v3.26.1
SCHEDULE OF NUMERATOR AND DENOMINATOR OF BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Details) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Accounting Policies [Abstract]    
Net income (loss) from continuing operations $ 397,687 $ (620,566)
Net income (loss) from discontinued operations 60,916 (2,906,817)
Less: Net loss attributable to noncontrolling interests from continuing operations (354) (206)
Net income (loss) attributable to Sanara MedTech shareholders $ 458,957 $ (3,527,177)
Weighted average shares, basic 8,706,678 8,570,104
Dilutive effect of stock options 10,218
Dilutive effect of unvested shares 268,970
Weighted average shares, diluted 8,985,866 8,570,104
Net income (loss) per share, basic:    
Continuing operations $ 0.04 $ (0.07)
Discontinued operations 0.01 (0.34)
Net income (loss) per share of common stock, basic 0.05 (0.41)
Net income (loss) per share, diluted:    
Continuing operations 0.04 (0.07)
Discontinued operations 0.01 (0.34)
Net income (loss) per share of common stock, diluted $ 0.05 $ (0.41)